NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

IMHO, anyone is still talking about mPFS and mOS at this time is either an accidental or intentional FUDster, for 1) this topic has been exhausted, and 2) such time has long passed.

Instead we should look this way: whether the mPFS and/or mOS by the initial design is/are met or not shall serves as only a bonus. If yes, bravo to the company, patients and investors; if not, bears or those "enthusiasts" who have never had a position, I say you win in this debate in this specific issue, but DCVAX-L still has other way to win thanks to Linda's stubbornness or her out-of-touch approach or her unyielding will to not comfort to shorts demands to un-blind trial.

So what is the most important or sole important thing at this point of time is that we are looking at whether there is a long tail. If yes, how long and how fat it will be. This is and should be the only thing that matters now in terms of the chance of DCVax-L being approved by FDA, etc. (plus that bonus if it turns out be the way we expected--two strokes of luck!)

Focus on the following (others may just be FUD IMHO):

Blended Controlled Treatment(Early+Late) Treatment (Late only)
n n n n

1y
2y
3y
4y
5y

Repeat the same statistics based on sub-types and/or in reference with various historical data for all data.

If there is a substantial reduction of deaths between groups such as 25~ 65% or more reduction between control and treatment, or between early and late (vaccine receiving) treatment group, DCVax-L will get approved.